Risk of Respiratory Syncytial Virus Infection in Cyanotic Congenital Heart Disease in a Subtropical Area

被引:9
作者
Chiu, Shuenn-Nan [1 ,2 ]
Shao, Pei-Lan [3 ,4 ]
Chen, Hui-Chi [5 ]
Lin, Ming-Tai [1 ,2 ]
Huang, Li-Min [1 ,2 ]
Kao, Feng-Yu [6 ]
Huang, San-Kuei [6 ]
Wang, Jou-Kou [1 ,2 ]
Wu, Mei-Hwan [1 ,2 ]
机构
[1] Natl Taiwan Univ Hosp, Dept Pediat, 7 Chung Shan South Rd, Taipei 100, Taiwan
[2] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan
[3] Natl Taiwan Univ Hosp, Dept Lab Med, Hsin Chu Branch, Hsinchu, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Pediat, Hsin Chu Branch, Hsinchu, Taiwan
[5] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan
[6] Taiwan Natl Hlth Insurance Adm, Taipei, Taiwan
关键词
COST-EFFECTIVENESS; YOUNG-CHILDREN; PALIVIZUMAB; RATES; IMMUNOPROPHYLAXIS; HOSPITALIZATIONS; PROPHYLAXIS; INFANTS;
D O I
10.1016/j.jpeds.2015.12.029
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To compare the risk of respiratory syncytial virus (RSV)-associated hospitalization and analyze the epidemiology of RSV infection in patients with cyanotic and acyanotic congenital heart disease (CHD), we analyzed the nationwide health insurance database from 2005-2010. Study design This study included 1050 patients with cyanotic CHD and 7077 patients with acyanotic CHD. Patients with acyanotic CHD were further classified into hemodynamically significant (hs)-acyanotic and non-hs-acyanotic groups according to whether they underwent surgery or took at least 2 anticongestive medications. Results RSV-associated hospitalization was higher in the cyanotic group than in hs-acyanotic and non-hs-acyanotic groups both before 1 year of age (4.8% vs 2.1% vs 1.5%, P < .001) and between 1 and 2 years of age (0.9% vs 0.56% vs 0.14%, P = .003). The hospitalization duration, intensive care, ventilator support prevalence, hospitalization cost, and mortality rate were significantly higher in the cyanotic group than in the other 2 groups. Logistic regression revealed that cyanotic CHD was the most significant risk factor for the ventilator support and RSV-associated mortality. In both patients with cyanotic and acyanotic CHD, RSV-associated hospitalization rate was higher in patients aged younger than 1 year and in spring and autumn in Taiwan, a subtropical country. Conclusions The results show that patients with cyanotic CHD have a higher risk of severe RSV infection than do those with acyanotic CHD. RSV prophylaxis is more important and may reduce costs more for patients with cyanotic CHD.
引用
收藏
页码:25 / +
页数:7
相关论文
共 32 条
[1]  
Bocchini JA, 2009, PEDIATRICS, V124, P1216, DOI [10.1542/peds.2009-1806, 10.1542/peds.2009-2345]
[2]   Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid [J].
Boyce, TG ;
Mellen, BG ;
Mitchel, EF ;
Wright, PF ;
Griffin, MR .
JOURNAL OF PEDIATRICS, 2000, 137 (06) :865-870
[3]  
Brady MT, 2014, PEDIATRICS, V134, pE620, DOI [10.1542/peds.2014-1666, 10.1542/peds.2014-1665]
[4]   Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease [J].
Chang, Ruey-Kang R. ;
Chen, Alex Y. .
PEDIATRIC CARDIOLOGY, 2010, 31 (01) :90-95
[5]   A Novel Six Consecutive Monthly Doses of Palivizumab Prophylaxis Protocol for the Prevention of Respiratory Syncytial Virus Infection in High-Risk Preterm Infants in Taiwan [J].
Chi, Hsin ;
Hsu, Chyong-Hsin ;
Chang, Jui-Hsing ;
Chiu, Nan-Chang ;
Hung, Han-Yang ;
Kao, Hsin-An ;
Weng, Li-Chuan ;
Huang, Fu-Yuan ;
Chiu, Yu-Ying ;
Chang, Luan-Yin ;
Huang, Li-Min .
PLOS ONE, 2014, 9 (06)
[6]   Palivizumab use in subjects with congenital heart disease: Results from the 2000-2004 Palivizumab Outcomes Registry [J].
Cohen S.A. ;
Zanni R. ;
Cohen A. ;
Harrington M. ;
Vanveldhuisen P. ;
Boron M.L. .
Pediatric Cardiology, 2008, 29 (2) :382-387
[7]   Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease [J].
Duppenthaler, A ;
Ammann, RA ;
Gorgievski-Hrisoho, M ;
Pfammatter, JP ;
Aebi, C .
ARCHIVES OF DISEASE IN CHILDHOOD, 2004, 89 (10) :961-965
[8]   Population-based rates of severe respiratory syncytial virus infection in children with and without risk factors, and outcome in a tertiary care setting [J].
Eriksson, M ;
Bennet, R ;
Rotzén-Östlund, M ;
von Sydow, M ;
Wirgart, BZ .
ACTA PAEDIATRICA, 2002, 91 (05) :593-598
[9]   Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease [J].
Feltes, TF ;
Cabalka, AK ;
Meissner, C ;
Piazza, FM ;
Carlin, DA ;
Top, FH ;
Connor, EM ;
Sondheimer, HM .
JOURNAL OF PEDIATRICS, 2003, 143 (04) :532-540
[10]   Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis in Various Indications [J].
Hampp, Christian ;
Kauf, Teresa L. ;
Saidi, Arwa S. ;
Winterstein, Almut G. .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2011, 165 (06) :498-505